Seeking Alpha·Jun 30, 2026
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy TranscriptPlus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
Plus Therapeutics, Inc.(PSTV)Earnings, Financials & Key Ratios
PSTV•NASDAQ
$3.92
Price updated Jul 7, 2026
AboutPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.Show more
- Revenue$5M-10.5%
- EBITDA-$15M-7.3%
- Net Income-$22M-72.5%
- EPS (Diluted)-7.19+87.7%
- Gross Margin91.46%+7.1%
- EBITDA Margin-284.92%-19.9%
- Operating Margin-293.46%-16.3%
- Net Margin-429.43%-92.7%
- ROE-560.21%
PSTV Price & Volume
Plus Therapeutics, Inc. (PSTV) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Radiopharmaceutical Development Pipeline
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Plus Therapeutics faces a precarious financial outlook characterized by a reliance on non-recurring grant revenue and significant operational losses that consistently outpace income.
- The company's heavy investment in specialized infrastructure, evidenced by a 79.6% capital intensity ratio in 2026Q1, necessitates frequent external financing that risks further shareholder dilution.
- Investors should monitor the firm's ability to achieve clinical milestones, as the current trajectory of negative net margins and dwindling cash reserves suggests a high-risk profile for long-term capital preservation.
Verdict Logic
the company's persistent net losses, which reached $6.9M in 2026Q1, combined with a rapid depletion of liquidity, suggest an unsustainable business model that requires constant dilutive financing.
PSTV Growth Metrics
Plus Therapeutics, Inc. (PSTV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.73%
5 Years76.66%
3 Years185.5%
TTM-0.46%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.73%
Return on Capital
10 Years-149.53%
5 Years-214.68%
3 Years-295.79%
Last Year-381.4%
PSTV Recent Earnings
Plus Therapeutics, Inc. (PSTV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$1.05-23.8%
$0.85
Rev
$1M+5.5%
$974,000
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.83-4.2%
$0.80
Rev
$1M+10.6%
$1M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.04-100.0%
$0.02
Rev
$1M-6.5%
$1M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.01+88.9%
$0.09
Rev
$1M-6.5%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.05vs $0.85-23.8% | $1Mvs $974,000+5.5% |
| Q2 2026 | Mar 12, 2026 | $0.83vs $0.80-4.2% | $1Mvs $1M+10.6% |
| Q4 2025 | Oct 30, 2025 | $0.04vs $0.02-100.0% | $1Mvs $1M-6.5% |
| Q3 2025 | Aug 14, 2025 | $0.01vs $0.09+88.9% | $1Mvs $1M-6.5% |
Based on last 12 quarters of dataView full earnings history →
Latest PSTV News
Recent stock market news and headlines for Plus Therapeutics, Inc. (PSTV)
GlobeNewsWire·Jun 30, 2026
Plus Therapeutics Provides Mid-Year Business Update Including Corporate RebrandingPlus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company focused on central nervous system (“CNS”) cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026.
GlobeNewsWire·Jun 25, 2026
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerHOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people.
GlobeNewsWire·Jun 23, 2026
Plus Therapeutics to Provide Business Update Call on June 30, 2026Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans
Peers Comparison
Key metrics vs top competitors for Plus Therapeutics, Inc. (PSTV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.92 | $9.48M | -0.55 | -10.49% | -429.43% | -560.21% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $17.46 | $1.36B | -2.59 | 1.53% | -30.15% | -47.65% | — | |
| $4.45 | $429.82M | 20.23 | 133.2% | -8.53% | -3.18% | — |
Compare PSTV vs Peers
Plus Therapeutics, Inc. (PSTV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PSTV SEC Filings & Documents
Plus Therapeutics, Inc. (PSTV) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Jun 5, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 15, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when PSTV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PSTV Frequently Asked Questions
Plus Therapeutics, Inc. (PSTV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Plus Therapeutics, Inc.'s revenue?
Plus Therapeutics, Inc. (PSTV) reported $5.2M in revenue for fiscal year 2025.
How fast is Plus Therapeutics, Inc. growing?
Plus Therapeutics, Inc. (PSTV) saw revenue decline by 10.5% over the past year.
Is PSTV profitable?
Plus Therapeutics, Inc. (PSTV) reported a net loss of $11.9M for fiscal year 2025.
Dividend & Returns
What is PSTV's return on equity?
Plus Therapeutics, Inc. (PSTV) has a return on equity (ROE) of -560.2%. Negative ROE indicates the company is unprofitable.
What is Plus Therapeutics, Inc.'s free cash flow?
Plus Therapeutics, Inc. (PSTV) had negative free cash flow of $21.7M in fiscal year 2025, likely due to heavy capital investments.